The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Approximately five kg tumor was removed in the eight-hour long complicated surgery
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
The hospital is scheduled to open in 2024 with a bed capacity of 225
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Subscribe To Our Newsletter & Stay Updated
